Surat-based hybrid pharmaceutical formulations maker exporting tablets, capsules and other dosage forms under own brands and via contract/loan-license manufacturing to Africa, Latin America, CIS and East Asia.
Price
Market Cap
Sector
Healthcare
Rank
| Line item | FY22 | FY23 | FY24 | FY25 | FY26 | FY26 |
|---|---|---|---|---|---|---|
| LiabilitiesEquity Capital | 8 | 12 | 12 | 12 | 12 | 12 |
| Reserves | -3 | 34 | 41 | 53 | 69 | 88 |
| Borrowings | 2 | 8 | 18 | 54 | 59 | 73 |
| Other Liabilities | 7 | 9 | 16 | 37 | 47 | 63 |
| Total Liabilities | 14 | 63 | 87 | 156 | 187 | 237 |
| AssetsFixed Assets | 1 | 3 | 21 | 44 | 46 | 61 |
| CWIP | 0 | 5 | 4 | 2 | 2 | 18 |
| Investments | 0 | 3 | 4 | 11 | 9 | 8 |
| Other Assets | 12 | 51 | 58 | 99 | 130 | 150 |
| Total Assets | 14 | 63 | 87 | 156 | 187 | 237 |
| Line item | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| ActivitiesCash from Operating | 0 | -19 | 2 | -10 | 5 |
| Cash from Investing | 0 | -10 | -20 | -14 | -37 |
| Cash from Financing | 1 | 42 | 11 | 20 | 34 |
| SummaryCapital Expenditure | — | — | — | — | — |
| Free Cash Flow | -1 | -26 | -16 | -21 | -29 |
| FCF Margin | — | — | — | — | — |
The Earnings Per Share over the last 12 months.
Your assumption of the company's expected yearly EPS growth (e.g., 6 for 6%).
Pre-filled with the lower of median (21.6×) and current (15.9×) PE — the conservative anchor.
The annualized return you aim to achieve. We solve for the price that delivers it, then compare to today's price.
At 26.8% growth and a 16× exit, ₹244 only delivers your return if you pay ₹374. The price is currently baking in 17% growth.
EPS grows 26.8%/yr for 5 years, then fades to 6% over 2, exits at 16×.
| Year | Growth | EPS (₹) |
|---|---|---|
| FY27 | 26.8% | 19.51 |
| FY28 | 26.8% | 24.74 |
| FY29 | 26.8% | 31.38 |
| FY30 | 26.8% | 39.78 |
| FY31 | 26.8% | 50.45 |
| FY32 | 16.4% ·fade | 58.72 |
| FY33 | 6.0% ·fade | 62.24 |
Methodology: we discount normalized net profit as a proxy for owner earnings (an earnings-power approximation — not full free cash flow). Terminal growth is capped at 6% (≈ nominal GDP) regardless of the required return. This is an analytical tool, not investment advice.
Guides on how to read this kind of business and the numbers that matter.